Ludwig-Maximilians-Universität München

Running trials

• Not yet recruiting

  Stratification and Treatment in Early Psychosis Study -ASSIST

  NCT07326124· Phase 3· Source

• Not yet recruiting

  A Phase 1/2/3 Study of ATSN-201 Gene Therapy in Subjects with RS1-Associated X linked Retinoschisis

  NCT05878860· Phase 3· Source

• Recruiting

  Stratification and Treatment in Early Psychosis Study - ENHANCE

  NCT06778564· Phase 3· Source

• Recruiting

  Dehydroepiandrosterone (DHEA) as Augmentation of Standard Antidepressants in Treatment-resistant Depression.

  NCT07843927· Phase 3· Source

• Recruiting

  TRICuspid Intervention and Invasive Hemodynamic Monitoring in Heart Failure

  NCT07442903· Source

• Active, not recruiting

  COMBINED PSMA-PET/CT AND MRI STAGING IN INTERMEDIATE AND HIGH-RISK PATIENTS PROSTATA-CANCER (COMBINE-P)

  NCT07455097· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B

  NCT07285460· Phase 3· Source

• Not yet recruiting

  An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia

  NCT06281847· Phase 1/2· Source

• Not yet recruiting

  A Phase 2 Trial Evaluating the Effects of Thiethylperazine as diagnostic tool and therapeutic agent in Patients Diagnosed with an Early Stage of Alzheimer's disease

  2022-501137-23-00· Phase 2· Source

• Recruiting

  Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

  NCT06990269· Phase 2· Source

• Recruiting

  PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis

  NCT06855329· Source

• Active, not recruiting

  A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME

  NCT06957080· Phase 2/3· Source

• Recruiting

  Fast Discharge After Acute Myocardial Infarction Discharge MI

  NCT06744322· Source

• Active, not recruiting

  A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF (in patients with Diabetic Macular Edema)

  2024-510944-30-00· Phase 2/3· Source

• Active, not recruiting

  Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer

  NCT06178445· Phase 2· Source

• Recruiting

  CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA

  2023-503317-29-00· Phase 3· Source

• Recruiting

  LUPUS-BEST - Treat-to-target in Systemic Lupus Erythematosus

  NCT05714930· Source

• Recruiting

  Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD

  NCT05566769· Source

• Recruiting

  Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene

  NCT06291935· Phase 1· Source

• Recruiting

  Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing as Usual in Psychiatric Disorders

  NCT05656469· Phase 4· Source

• Recruiting

  A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C

  NCT05163288· Phase 3· Source

• Active, not recruiting

  AMP SCZ® Observational Study: PREDICT-DPACC

  NCT05905003· Source

• Active, not recruiting

  Prognostic Role of Circulating Tumor DNA in Resectable Pancreatic Cancer

  NCT04246203· Source

• Recruiting

  High Dose Steroids in Children With Stroke

  NCT04873583· Phase 3· Source

• Active, not recruiting

  A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

  NCT05048797· Phase 3· Source

• Recruiting

  ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

  NCT05059444· Source

• Active, not recruiting

  A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

  NCT04657289· Phase 3· Source

• Recruiting

  Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).

  NCT04663750· Phase 3· Source

• Active, not recruiting

  Optimal Timing of Transcatheter Aortic Valve Implantation and Percutaneous Coronary Intervention - The TAVI PCI Trial

  NCT04310046· Source

• Active, not recruiting

  Comparison of Carboplatin and Cisplatin in patients with extracranial malignant germ cell tumours

  2023-507582-25-00· Phase 3· Source

• Recruiting

  Extension Study for the Port Delivery System With Ranibizumab (Portal)

  NCT03683251· Phase 3· Source

• Active, not recruiting

  Reducing Lung CongestIon Symptoms in Advanced Heart Failure

  NCT03499236· Source

• Active, not recruiting

  Paediatric Hepatic International Tumour Trial

  NCT03017326· Phase 3· Source

• Recruiting

  REtroperitoneal SArcoma Registry: an International Prospective Initiative

  NCT03838718· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Macular degeneration3 recruiting
• Schizophrenia3 recruiting
• Depression2 recruiting
• Kidney cancer2 recruiting
• Retinitis pigmentosa2 recruiting
• Acute myeloid leukemia1 recruiting
• Alzheimer disease1 recruiting
• Bipolar disorder1 recruiting
• Bladder cancer1 recruiting
• Childhood cancers1 recruiting
• Colorectal cancer1 recruiting
• Coronary artery disease1 recruiting
• Endometrial cancer1 recruiting
• Frontotemporal dementia1 recruiting
• Gastric and esophageal cancer1 recruiting
• Haemophilia1 recruiting
• Head and neck cancer1 recruiting
• Heart failure1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Liver and biliary tract cancer1 recruiting
• Lung cancer1 recruiting
• Lupus (SLE)1 recruiting
• Melanoma1 recruiting
• Neuromyelitis optica (NMOSD)1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Sarcoma1 recruiting
• Stroke1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Active, not recruiting

  A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC

  2023-504753-12-00· Phase 3· Source

• Completed

  A Two-Part Study to Assess the Effectiveness, Safety, and Blood Levels of Repeat Doses of Inhaled ETD001 in People with Cystic Fibrosis

  2023-504092-25-00· Phase 2· Source

• Completed

  Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

  NCT05819359· Phase 2· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)

  NCT05170204· Phase 3· Source

• Completed

  Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

  NCT05536297· Phase 3· Source

• Active, not recruiting

  A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

  NCT05374512· Phase 3· Source

• Active, not recruiting

  A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

  NCT05120349· Phase 3· Source

• Completed

  Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.

  NCT05158387· Phase 3· Source

• Terminated

  MR-Guided Adaptive SBRT of Primary Tumor for Pain Control in Metastatic PDAC

  NCT05114213· Phase 2· Source

• Active, not recruiting

  A Long-term Extension Study of Ustekinumab in Pediatric Participants

  NCT05092269· Phase 3· Source

• Completed

  A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

  NCT04673357· Phase 3· Source

• Completed

  A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)

  NCT04630028· Phase 3· Source

• Completed

  Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation

  NCT04392947· Source

• Completed

  Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer

  NCT04257448· Phase 1/2· Source

• Completed

  A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib

  NCT03535740· Phase 2· Source

• Completed

  Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

  NCT03422822· Phase 3· Source

• Completed

  Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

  NCT03036488· Phase 3· Source

Trial sites

• LMU München1 trial
• LMU Munich1 trial
• Ludwig-Maximilians-Universitat Munchen3 trials
• Ludwig Maximilian University of Munich1 trial
• LMU München0 trials
• LMU Munich3 trials
• LMU Munich, Department of Neurology0 trials
• Ludwig-Maximilians-Universitaet Muenchen14 trials
• Ludwig-Maximilians-Universitaet Muenchen - Campus Grosshadern0 trials
• Ludwig-Maximilians-Universität München0 trials
• Ludwig-Maximilians-Universität Munich1 trial
• Ludwig Maximilians University Munich4 trials
• Ludwig-Maximilians University of Munich1 trial
• Ludwig Maximilian University1 trial
• Ludwig Maximilian University Munich4 trials
• Ludwig Maximilian University Of Munich14 trials
• University Munich1 trial
• University of Munich1 trial
• University of Munich, Dep. of Radiation Oncology1 trial

Conditions

Diseases this institution publishes on or runs trials for.

• Alzheimer disease218 works · 1 trials
• Stroke191 works · 1 trials
• Obesity124 works · 0 trials
• Heart failure119 works · 2 trials
• Schizophrenia104 works · 4 trials
• Lung cancer101 works · 6 trials
• HIV88 works · 0 trials
• Asthma85 works · 0 trials
• Parkinson disease77 works · 1 trials
• Glioblastoma74 works · 0 trials
• Prostate cancer70 works · 1 trials
• Melanoma61 works · 1 trials
• Epilepsy60 works · 0 trials
• Colorectal cancer57 works · 1 trials
• Tuberculosis56 works · 0 trials
• Coronary artery disease54 works · 2 trials
• Atopic dermatitis (eczema)53 works · 1 trials
• Chronic kidney disease50 works · 0 trials
• Bipolar disorder48 works · 1 trials
• Sarcoma48 works · 1 trials
• Multiple sclerosis45 works · 0 trials
• Bladder cancer43 works · 1 trials
• Depression42 works · 3 trials
• Acute myeloid leukemia42 works · 1 trials
• Idiopathic pulmonary fibrosis39 works · 1 trials
• Frontotemporal dementia36 works · 1 trials
• Ovarian cancer34 works · 1 trials
• Pancreatic cancer34 works · 4 trials
• COPD30 works · 1 trials
• Migraine28 works · 0 trials